Naibec Achieves Record-High Sales in First Half of the Year... "Expecting Full-Scale Growth of Bone Regeneration Biomaterials"

[Asia Economy Reporter Hyunseok Yoo] Naivek, a peptide fusion bio-specialized company, achieved its highest-ever sales in the first half of this year, reaching 90% of last year's annual sales.

On the 17th, Naivek announced through its semi-annual report that sales in the first half of this year increased by 112% compared to the same period last year, reaching 5.7 billion KRW, and second-quarter sales increased by 160% compared to the same period last year, reaching 3.5 billion KRW. Due to the expansion of joint research with multiple global pharmaceutical companies for the application of drug delivery platforms and new drug development pipelines, research and development costs increased, resulting in operating losses of 1.9 billion KRW and 1 billion KRW for the same periods, respectively.

The sales growth in the first half was due to increased exports of bone regeneration bio-materials to the European region. Naivek obtained the European CE certification for bone regeneration bio-materials in 2012 and sells them in Europe through global implant companies.

A Naivek official stated, “In the second half of the year, exports of bone regeneration bio-materials to China are also expected to begin in earnest following Europe,” and added, “As individual country approvals are obtained in China, Russia, and others, the company's sales are expected to steadily increase centered on bio-materials (bone regeneration bio-materials and periodontal tissue regeneration materials) starting from the second half of this year.”

He continued, “The results of research and development so far are sequentially leading to sales growth, resulting in steady cash inflows,” and added, “Unlike other bio research and development companies, Naivek covers a significant portion of its research and development costs through its own sales activities.”

Naivek is conducting research and development on dental bio-materials, antibody-based drug delivery platforms, and gene-based (mRNA) drug delivery platforms. Its main pipelines include ▲ osteoporosis treatment (NIPE-OSS) ▲ non-alcoholic steatohepatitis treatment (NIPE-NASH) ▲ pulmonary fibrosis treatment (NIPE-PF) ▲ inflammatory bowel disease treatment (NIPE-IBD) ▲ COVID-19 treatment (NIPE-ACOV) ▲ mutant KRAS-targeted anticancer treatment.

This content was produced with the assistance of AI translation services.